A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Terumo Introduces New AZUR™ Vascular Plug and PG Pro™ Peripheral Microcatheter Embolization System

Terumo Medical Corporation (TMC) has announced today the introduction of its AZUR™ Vascular Plug, the first and only plug compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo’s robust embolization portfolio is indicated for use to reduce or block the rate of blood flow in arteries of the peripheral vasculature.

“The AZUR™ Vascular Plug represents a balance of properties – stability, accuracy, and reliable occlusion. This technology has unique advantages that truly make it a market first in embolotherapy, in line with Terumo’s ongoing efforts to deliver improved clinical outcomes and economic benefits,” said Chris Pearson, Executive Vice President, Commercial Operations, Terumo Interventional Systems.

The AZUR™ Vascular Plug comes in sizes to treat arterial anatomy ranging from 2.5mm to 8mm, with a short deployment length for increased precision. Features include a conformable nitinol braid that stays in place, even in tortuous anatomy. It also comes with a polytetrafluoroethylene (ePTFE) and polyethylene terephthalate (PET) inner composite membrane to facilitate mechanical occlusion. Another key element in the Plug’s design is its advanced, predictable detachment mechanism that allows for immediate and reliable deployment with the push of a button. Consistent with Terumo’s existing Azur coil portfolio, this state-of-the-art detachment mechanism can allow for a full ability to reposition, while making the process much smoother than traditional twist-off detachment mechanisms.

The launch of AZUR™ Vascular Plug is complemented by the introduction of the PG Pro™ Peripheral Microcatheter, which is indicated for the peripheral vasculature for the infusion of diagnostic and therapeutic agents. The PG Pro™ Microcatheter is designed specifically to deliver all three sizes of the Azur™ Vascular Plug. It comes in radial lengths up to 165 centimeters and a 1200 PSI rating for clearer fluoroscopic imaging. Both are currently only available in the United States.

“Together, these next-generation technologies allow physicians to treat larger, more difficult vessels through smaller delivery options. It is yet another way Terumo is providing the opportunity for operators to take advantage of the benefits of radial access for increasingly complex procedures, while enhancing therapeutic options in the peripheral vasculature with a microvascular plug. It is a welcome addition to our innovative, best-in-class portfolio,” added Michael Martinelli, MD, Chief Medical Officer, Terumo Medical Corporation.

This device should only be used by physicians who have undergone training in the use of the Azur system for embolization procedures as described by a representative from Terumo or a Terumo-authorized distributor. This device is intended for single use only. Do not reuse, reprocess or resterilize. Reuse, reprocessing or resterilization may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness, or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness or death of the patient.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy